CervoMed: Regulation Fd Disclosure, The Information Set Forth In The First And Third Paragraphs Of, And Under The Headings “recent Nature Neuroscience Publication Supports Inhibition Of P38α As Potential Therapeutic Approach In Ftd,” And “interim Results From The Phase 2a Clinical Trial To Be Presented At Ctad” In, The Company’s Press Release Issued On July 9, 2026, Is Incorporated By Reference Into This Item 8.01 Of This Currentreportonform8k, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  CervoMed Inc
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***